Welcome
Support Centre
06 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Complementary Alternative Medicine for Reconstitution of CD4 count and Quality of Life in HIV-Infected Patients with Advanced Disease
ISRCTN ISRCTN03831044
ClinicalTrials.gov identifier
Public title Complementary Alternative Medicine for Reconstitution of CD4 count and Quality of Life in HIV-Infected Patients with Advanced Disease
Scientific title HIV-Infected Patients with Advanced Disease in treatment with HAART use Complementary Alternative Medicine for Reconstitution of CD4 count and for Improving their Health Related Quality of Life over Time
Acronym N/A
Serial number at source N/A
Study hypothesis To describe if complementary alternative medicine (CAM) improves CD4 count and health related quality of life (HRQOL) in subjects presenting low naïve CD4 count and poor CD4 rise despite of good virologic response on highly active antiretroviral treatment (HAART).
Ethics approval The ethics commission of the Hospital San Juan de Dios approved the study design in August 2007.
Study design Single centre longitudinal case-control study
Countries of recruitment Chile
Disease/condition/study domain HIV-Infected Patients with Advanced Disease under HAART
Participants - inclusion criteria 1. Any adult patient infected with HIV who has a naïve CD4 count < 200 cell/mL and who, despite > 48 weeks of HAART, keep CD4 < 250 cell/mL
2. Adherent to HAART and to the controls with the physician in charge of treatment of the HIV-condition
3. Patients who modify their HAART regimens are not excluded if plasma HIV-1 RNA levels, remain < 80 copies/mL
Participants - exclusion criteria Patients who use hydroxyurea, IL-2, IFN-α, or the combination of tenofovir and didanosine, which are known to affect CD4 count increases
Anticipated start date 05/06/2007
Anticipated end date 05/06/2012
Status of trial Ongoing
Patient information material Not available in web format, please use contact details below to request a patient information sheet
Target number of participants 15 patients from the Hospital San Juan de Dios, Santiago, Chile
Interventions The same physician will be in charge of the CAM treatment throughout, indicating treatment, controlling its effects, adjusting therapy and also indicating additional controls with the physician in charge of HIV if needed. The controls in the program are every 2 to 8 weeks.
CAM will combine different therapeutic aspects:
1. All patients receive homeopathy and Bach-Flowers
2. Some cases will receive phytotherapy, consisting of Engystol®, propolis and/or aloe vera
3. Dietary advice, patients to reduce intake of any artificial substances like sweeteners, colourings and preservatives, and also substances like tobacco and alcohol
4. Patients open to body-mind-medicine will be taught a meditation technique by the CAM physician with creative visualization recovering sensations of health, well-being and peace

The homeopathic medicine is applied according the homeopathic constitutional integrated conception (presented in the 7° Congress of the Federation of Medical Homeopathic Argentinean Associations) whose main feature is that the homeopath has to identify the inner conflict of the patient leading to his current condition.

The medication is prepared at all times in the same homeopathic pharmacy under supervision of the same pharmacist. The patient has to fetch his prescription in the pharmacy.

Results are compared with the patient's CD 4 rise before intervention and the expected behaviour of CD 4 rise in these type of patients.
Primary outcome measure(s) 1. CD4 cell count and viral load, measured every 3 months
Viral load was considered undetectable with < 80 UI/mL copies using Nuclisens Easy Q HIV-1, Bio Mérieux test
2. Quality of Life, measured by Medical Outcomes Study Short Form 30 (MOS-SF-30) validated for people infected by HIV, answered privately by the patient every 3 months
Secondary outcome measure(s) 1. Incidence of hospitalisation
2. Opportunistic infection
3. Death
4. Side effects of CAM
5. Interaction of HAART and CAM
Sources of funding 1. Hospital SAn Juan de Dios (Chile) - internal funding
2. Laboratory Heel (Chile) - provides homeopathic medicine and Engystol
3. Mr. M Cavieres (Local provider) (Chile) - provides Propolis
4. Dr. Iris von Hörsten (Chile) - provides the Bach-Flowers
Trial website
Publications
Contact name Dr  Iris   von Hörsten
  Address Eliecer Parada 2030, Providencia
  City/town Santiago de Chile
  Zip/Postcode 7510931
  Country Chile
  Email irisvh@vtr.net
Sponsor Hospital San Juan de Dios (Chile)
  Address c/o Dr Iris von Hörsten
Eliecer Parada 2030
Providencia
  City/town Santiago de Chile
  Zip/Postcode 7510931
  Country Chile
Date applied 27/06/2010
Last edited 08/07/2010
Date ISRCTN assigned 08/07/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central